=Puma Biotech (PBYI) reported earnings on Thu 9 Nov 2017 (a/h)

Puma Biotech. beats by $0.07, beats on revs 

• Reports Q3 (Sep) loss of $1.36 per share, excluding non-recurring items, $0.07 better than the two analyst estimate of ($1.43); revenues were $6.1 mln vs the $3.78 mln Capital IQ Consensus.
• Net cash used in operating activities for the third quarter of 2017 was $54.9 million. Net cash used in operating activities for the nine months ended September 30, 2017 was $136.9 million. At September 30, 2017, Puma had cash and cash equivalents of $79.7 million and marketable securities of $26.6 million, compared to cash and cash equivalents of $194.5 million and marketable securities of $35.0 million at December 31, 2016.
• "Looking forward, we anticipate the following milestones: (i) reporting additional data from the Phase II CONTROL trial in the fourth quarter of 2017; (ii) receiving a regulatory opinion from the Committee for Medicinal Products for Human Use (CHMP) for neratinib in extended adjuvant HER2-positive early stage breast cancer in the first quarter of 2018; and (iii) reporting Phase III trial results in third-line HER2- positive metastatic breast cancer patients in the first half of 2018."